

# Gender Differences in HIV, HCV risk and Prevention Needs Among People who Inject drug in Vietnam

Hoang Thi Giang, Nguyen Quang Duc, Pham Minh Khue, Catherine Quillet, Khuat Thi Hai Oanh, Nham Thi Tuyet Thanh, Roselyne Vallo, Jonathan Feelemyer, Vu Hai Vinh, Delphine Rapoud, et al.

# ▶ To cite this version:

Hoang Thi Giang, Nguyen Quang Duc, Pham Minh Khue, Catherine Quillet, Khuat Thi Hai Oanh, et al.. Gender Differences in HIV, HCV risk and Prevention Needs Among People who Inject drug in Vietnam. AIDS and Behavior, In press, 10.1007/s10461-022-03932-x. hal-03876988

# HAL Id: hal-03876988 https://hal.science/hal-03876988v1

Submitted on 29 Nov 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. **ORIGINAL PAPER** 



# Gender Differences in HIV, HCV risk and Prevention Needs Among People who Inject drug in Vietnam

Hoang Thi Giang<sup>1</sup> · Nguyen Quang Duc<sup>1</sup> · Pham Minh Khue<sup>1</sup> · Catherine Quillet<sup>2</sup> · Khuat Thi Hai Oanh<sup>3</sup> · Nham Thi Tuyet Thanh<sup>3</sup> · Roselyne Vallo<sup>2</sup> · Jonathan Feelemyer<sup>4</sup> · Vu Hai Vinh<sup>5</sup> · Delphine Rapoud<sup>2</sup> · Laurent Michel<sup>6</sup> · Didier Laureillard<sup>2,7</sup> · Jean Pierre Moles<sup>2</sup> · Don Des Jarlais<sup>4</sup> · Nicolas Nagot<sup>2</sup> · Duong Thi Huong<sup>1</sup>

Accepted: 12 November 2022 © The Author(s) 2022

#### Abstract

We examined gender differences among people who inject drug (PWID) in Hai Phong, Vietnam in term of blood-borne infections, risk behaviors, and access to care. Using respondent-driven-sampling surveys, we recruited 3146 PWID from 2016 to 2018. Inclusion criteria included a positive urine test for heroin and recent injection marks. There were 155 female PWID (4,9%), including 82 at RDS-2016, 32 at RDS-2017 and 38 at RDS-2018. The age mean was  $36.3 \pm 7.2$  years. The majority of female PWID had less than high school education (90.9%) and were unemployed (51.3%). There was no difference in the proportion of HIV and HCV positive by gender. However, women had several significant differences in risk behaviors than men in multivariable logistic regression. Being a woman was independently associated with being unemployed, being a sex worker, having unstable housing, having uses drugs for less than 5 years, more use of meth-amphetamine, having a partner who ever injected drugs, and less access to methadone treatment. Interventions targeting female PWID are needed, possibly through community organizations and peer educators.

Keywords Women · People who inject drugs · HIV risk · Prevention needs · Vietnam

## Introduction

Globally, the number of people who inject drugs (PWID) is approximately 11 million, of whom 1.4 million are living with HIV and 5.6 million with hepatitis C (HCV) according to World Drugs Report - UNODC 2019 [1]. No global population size estimates of females who inject drugs (FWID) are available, and data gaps exist in nearly all countries. According to recent estimates, FWID range from 10% to over 30% in some parts of Europe; approximately 20% in Eastern Europe, Central Asia and Latin America; 10-20% in parts of Africa; 20% in China and Viet Nam, and at least 10% in other parts of Asia, corresponding to approximately 3.5 million FWID globally [2, 3]. A previous study has shown variation in the female: male odds ratios for HIV prevalence but overall there was a modest but significantly higher HIV prevalence among females with an overall odds ratio of 1.18. FWID also had higher rates of infection compared to male who inject drugs (MWID) in

Published online: 28 November 2022

Eastern Europe (33.0% vs. 27.9%), Western Europe (42.8% vs. 40.3%), Latin America (38.5% vs. 34.6%) and North America (34.5% vs. 31.3%) [2].

In addition to the risk of HIV and HCV exposure, FWID face multilevel drivers that increase their vulnerabilities to sexually transmitted diseases, impaired physical and mental health [4], particularly among female sex workers. FWID experience stigma and discrimination, including from within drug user networks, due to gendered social norms and the role of women as primary care givers. This may affect access to treatment and prevention services, and may also lead to higher levels of sexual risk exposures [2, 5, 6]. In many settings, sex work is criminalized, with legal sanctions directed towards women who engage in sex work rather than their clients, who are predominantly men [7]. Violence, or the threat of violence, is also a significant contributor to HIV and HCV risk behaviors among PWID, serving to undermine women's ability to practice safe sex and safer drug use with intimate partners [8] and during sex work [7]. In some regions of Africa, women who have experienced physical or sexual intimate partner violence are 1.5 times more likely to acquire HIV than women who have not

Extended author information available on the last page of the article

experienced such violence [9]. The results from a nationwide survey among Iranian female sex workers showed that female sex workers with high levels of sexual activity use more drugs than those with less activity. The main reason was that they know drug use is an effective factor in reducing depression or obsessive-compulsive disorder, and know that drugs can help eliminate sexual reluctance, increase emotional tendencies, increase pleasure in sexual relationships, and prevent sexual disputes. Hence, those that use drugs are able to have more customers every day and earn more money [10].

In Vietnam, there are an estimated 189,000 PWID and HIV prevalence among PWID was 12.7% in 2020 [11], with large variations across regions. Injecting drug use remains the leading HIV transmission mode in Vietnam, although the rate of transmission among MSM is approaching parity [11]. Modelling in 2018 estimated that 25% of new infections occurred among PWID including 37% among women at low risk and 2% among female sex workers [12]. Mortality rates among PWID remain high in Vietnam despite very successful HIV and methadone programs. Crude mortality rates are approximately 4.3 (95% Confidence interval (CI): 3.3–5.4) per 100 person-years of follow-up (PYFU) among HIV-positive PWID and 1.9 (CI: 1.4-2.6) per 100 PYFU among HIV-negative PWID. The main causes of death are tuberculosis and HIV-related diseases in the HIV-positive group, while the main causes of death are liver-related diseases and overdose in the HIV-negative group [13].

PWID also report high levels of stigma from their communities, which are often amplified in the presence of HIV infection and make it difficult for PWID to earn money, which in many cases places the burden of care on their families [14]. Beyond physical morbidity and mortality, drug use carries a significant mental health burden; 25.5% had at least one psychiatric disorder and 10.1% had 2 or more psychiatric disorders after 12 month's follow-up in Haiphong in 2016 and FWID were more likely than males to have at least one psychiatric disorder, a major depressive disorder, or an anxiety disorder [15]. Nevertheless, data on the health risks of women who use and inject drugs are still scarce. The lack of data regarding risks among FWID, including female sex workers, transgender women, racial and ethnic minority women, and young women may affect the efficiency of HIV control efforts.

Haiphong city is one of the largest cities in Vietnam with approximately 2 million inhabitants and an estimated 10,000 PWID. The focused resources on addressing issues related to PWID such as antiretroviral treatment (ART), syringe-needle-exchange programs (SNEP) and medication for opioid use disorder (MOUD) have existed in this city for nearly 20 years [16–20]. In 2014, we conducted a respondent driven sampling survey (RDSS) among heroin

injectors in Haiphong to assess the efficiency of these prevention programs and estimate the incidences of HIV and HCV infections. We reported a low HIV incidence (between 0 and 1.8 per 100 person-years (PY), contrasting with a very high HCV incidence (19.4/100 PY, 95% CI:11.5–30.7) [21]. This paper aimed to assess the additional HIV and HCV risk, as well as the prevention and treatment needs of FWID in comparison to MWID in Haiphong city, Vietnam.

# Methods

## **Study Design**

We conducted a secondary analysis of data collected from 3 successive annual RDSS conducted in Hai Phong, Vietnam from 2016 to 2018 as part of the interventional Drugs & Infections in ViEtnam (DRIVE) research project. A case – control analysis was set with 1 FWID for 4 MWID. All the different FWID enrolled in the RDSS were selected as a "case group". Only data at first enrolment were considered if an FWID was recaptured during a subsequent RDSS. For the "control group", four MWID were randomly selected matching on age and RDSS date equivalent to each FWID case.

## Setting

The RDSS was implemented in Haiphong city with active involvement of seven community-based organization (CBO)s in several aspects of the study. The RDSS survey took place between October and January every year in two CBO offices (Light House and Friendship Arms).

### **Study Population and Study Conduct**

To construct the RDSS sample, twenty non-randomly identified "seeds" were recruited by CBO members for each RDSS. These included PWID with short and long histories of injecting, sex workers who inject drugs, and men who have sex with men who inject drugs from various districts. They participated in all procedures and were then instructed on how to recruit new study participants using the RDSS coupons from their injecting drug user's networks. Each coupon was valid for one week. The proportion of coupons that were returned for inclusion in the RDSS was approximately 30% for each RDSS and the proportion of seeds that generated 3 or more rounds of responses was approximately 80% on average for the 3 RDSS. The network size of each participant was collected in RDSS Coupon Manager® 3.0 software. The RDSS eligible criteria included:

- Being 18 years old and older,
- Living in Haiphong, Vietnam during the study period.
- Urine positive test for heroin and/or methamphetamine and recent injection marks on the skin examined by CBO members.

All eligible subjects who provided informed consent completed a questionnaire in Vietnamese, participating in a drug urinalysis test and a blood collection for HIV and HCV serology and for plasma banking by following an anonymous procedure at two community study sites located in urban Haiphong city. The interviewer administered a questionnaire on sexual behaviors, drug use and health care utilization. Participants were also screened for depression and anxiety using the PHQ4-scale (The Patient Health Questionnaire 4) [22]. All participants received \$7.50 for the interview, \$2.50 for transportation fees and \$2.50 for each peer they successfully recruited. They also received an additional \$2.50 to return to the study site to obtain their HIV and HCV test results one week after the RDSS. Subjects who screened HIV-positive were immediately referred to antiretroviral care. Participants were also referred to methadone treatment upon request.

# **HIV and HCV Testing**

HIV antibody and HCV antibody testing were conducted by the well-trained nurses of Haiphong Provincial AIDS Control Centre (PAC) at the study site using SD Bioline HIV1/2 3.0 rapid test and SD Bioline HCV rapid test (Standard Diagnostics Inc., Gyeonggi-do, Republic of Korea). HIV confirmation tests were done at PAC according to the National guidelines using Determine<sup>TM</sup> HIV-1/2 (Alere<sup>TM</sup>, Waltham, USA) plus the VIKIA® HIV1/2 test (Marcy-l'Etoile, Lyon, France) [23]. All the test results were returned to participants within 8 days after recruitment date.

### **Cascade of HIV care**

The HIV viral loads were quantitated using the COBAS HIV-1 test (Roche) in a reference laboratory. To identify PWID with ARV treatment failure, the plasma lamivudine (3TC), present in all local ART regimens, was tested by HPLC at Ho Chi Minh Pasteur Institution for all PWID with a HIV viral load of more than 1000 copies/mL.

#### **Data Analysis**

Data were analyzed using STATA software (version 15.1, Stata Corp, College Station, Texas, USA). Chi-square tests or t-tests were used to compare demographic and behavioral characteristics by gender. Bivariate and multivariable



Fig. 1 Participants' flow chart

logistic regression analysis were performed to explore the factors associated with gender. All variables with a p-value below 0.2 in the bivariate analysis were included in the multivariable analysis and the goodness-of-fit test was used to consider the suitability of the model by using McFadden's Pseudo R2 indicator [24]. A probability level of 0.05 or less was considered statistically significant.

We defined unsafe sex when a condom was not always used (i) during sexual intercourse with a primary partner with unknown or positive HIV status and (ii) during sexual intercourse with a casual partner. A cut-point of 6 was used to identify participants with moderate/severe anxiety/ depressive symptoms with the PHQ 4 [22].

# Results

### **Overall Female PWID Characteristics**

Of the 3146 PWID enrolled in the study over the 3 RDSS, 155 were FWID (4.9%), including 85 at RDSS-2016, 32 at RDS-2017 and 38 at RDSS-2018. Their mean age was  $36.3 \pm 7.2$  years (Fig. 1). The selection of MWID fulfilled the initial criteria with a mean age of  $36.8 \pm 7.1$  years (Table 1). Overall, the majority of FWID had less than high school education (90.9%) and were unemployed (51.3%). Eighty-six FWID (55.5%) had a monthly income of more than \$250. Only 61 FWID had a health insurance card (39.4%). Fifteen (9.7%) had unstable housing and 10 had experienced overdose to the point of unconsciousness (6.5%) in the last 6 months. 30% of the participants were confirmed HIV-positive, and 67.1% were HCV positive.

| Table 1 | Demographic, drug use,    |
|---------|---------------------------|
| psychos | ocial characteristics and |
| HIV and | HCV serostatus by         |
| gender  |                           |

|  | n = 620                 | n = 155                 | value (Chi-<br>Square or<br>T-test test) | r value |
|--|-------------------------|-------------------------|--|---------|
| Demographic characteristics  |                         |                         |  |         |
| Age (years) (mean ± SD)  | 36.8±7.1<br>[36.2–37.4] | 36.3±7.2<br>[35.1–38.4] | -  |         |
| High school graduate and more  | 166 (26.8)              | 14 (9.1)                | 21.89                                    | < 0.001 |
| Having ID card   | 371 (59.8)              | 86 (55.5)               | 0.97                                     | 0.324   |
| Having insurance health card   | 234 [37.7]              | 61 [39.4]               | 0.14                                     | 0.711   |
| Total monthly income $\geq$ \$250  | 253 (40.8)              | 78 (50.3)               | 4.59                                     | 0.032   |
| Unemployed   | 194 (31.3)              | 79 (51.3) <sup>a</sup>  | 21.04                                    | < 0.001 |
| Sex worker   | 9 (1.5)                 | 36 (23.2)               | 107.49                                   | < 0.001 |
| Unstable housing last 6 months   | 23 (3.7)                | 15 (9.7)                | 9.47                                     | 0.002   |
| Drug use behaviors   |                         |                         |  |         |
| Heroin injecting time < 5 years (primarily injected drug in Vietnam)                   | 162 (26.1)              | 59 (38.1)               | 8.67                                     | 0.003   |
| Number of injections per month   | $26.9\pm6.3$            | $27.3\pm6.4$            | -0.57*                                   | 0.568   |
| Number of injections per day   | $2.2\pm0.9$             | $2.5 \pm 1.0$           | -3.22*                                   | < 0.001 |
| Multi - drug use   | 452 (72.9)              | 123 (79.4)              | 2.7                                      | 0.101   |
| Non-injection drug use, last 6 months:   |                         |                         |  |         |
| Methamphetamine  | 440 (71.0)              | 121 (78.1)              | 3.12                                     | 0.077   |
| Cannabis   | 73 (11.8)               | 22 (14.2)               | 0.67                                     | 0.411   |
| Ketamine   | 28 (4.5)                | 9 (5.8)                 | 0.45                                     | 0.500   |
| Ecstasy  | 25 (4.0)                | 10 (6.5)                | 1.68                                     | 0.194   |
| Amphetamine  | 18 (2.9)                | 8 (5.2)                 | 1.95                                     | 0.162   |
| Cocaine  | 6 (1.0)                 | 3 (1.9)                 | 1.01                                     | 0.314   |
| Methamphetamine positive in urine  | 225 (36.3)              | 71 (45.8)               | 4.76                                     | 0.029   |
| Ever overdosed to the point of unconsciousness   | 27 (4.4)                | 10 (6.5)                | 1.2                                      | 0.273   |
| Psychosocial characteristics   |                         |                         |  |         |
| Depressive/anxiety symptoms within the last 2 weeks (PHQ4 scale, total score $\geq$ 6) | 52 (8.4)                | 18 (11.6)               | 1.57                                     | 0.210   |
| Thought of harming oneself   | 60 (9.7)                | 27 (17.4)               | 7.46                                     | 0.006   |
| Risky practices  |                         |                         |  |         |
| Unsafe sex activity  | 75 (12.1)               | 44 (28.4)               | 25.32                                    | < 0.001 |
| Partner ever injected drugs  | 14 (2.3)                | 59 (38.1)               | 186.33                                   | < 0.001 |
| Sharing needles/syringes/water   | 105 (16.9)              | 27 (17.4)               | 0.02                                     | 0.886   |
| HIV seroprevalence   | 174 (28.1)              | 47 (30.3)               | 0.31                                     | 0.577   |
| VL < 1000 copies/mL  | 140 (81.9) <sup>b</sup> | 33 (71.7) <sup>c</sup>  | 2.30                                     | 0.129   |
| HIV seroprevalence   | 433 (69.8)              | 104 (67.1)              | 0.44                                     | 0.508   |
| Methadone detected in urine  | 318 (51.3)              | 57 (36.8)               | 10.46                                    | 0.001   |
| Contact with peer-group  | 62 (10.0)               | 21 (13.6)               | 1.63                                     | 0.201   |

**X** ( 1

\* T- test; <sup>a</sup> one value missing; <sup>b</sup> three viral load result missing; <sup>c</sup> one viral load result missing

# Socio-demographic Characteristics by Gender

As shown in Table 1, FWID were significantly more unemployed than MWID (51.3% vs. 31.3%, Chi-square = 21.04, p < 0.001) and reported higher levels of unstable housing in the last 6 months compared to MWID (9.7% vs. 3.7%, Chi-square = 9.47, p < 0.01). FWID were more likely to have less than a high school education compared to MWID (90.9% vs. 73.2%, Chi-square = 21.89, p < 0.001). The percentage of FWID with an average monthly income of over \$250 was slightly higher than that of MWID (50.3% vs. 40.8%, Chi-square = 4.59, p < 0.05). There was no difference between

FWID and MWID with respect to having a health insurance card, having an identity card (Table 1) and reporting a history of being incarcerated overnight.

# Comparison of HIV/HCV Status and Associated risk Factors by Gender

There was no difference in the prevalence of HIV and HCV by gender (FWID vs. MWID: 30.3% vs. 28.1% and 67.1% vs. 69.8%, respectively). Similarly, there was no difference in the primarily injected drug by gender (~100% were injecting heroin). However, with respect to drug use behavior, FWID were more likely than MWID to report injecting



Fig. 2 HIV cascade of care on the background of 90-90-90 targets by gender

| Table 2 | Logistic | models   | of  | factors  | associated | with | being | female |
|---------|----------|----------|-----|----------|------------|------|-------|--------|
| among I | WID in H | Haiphong | , V | ietnam ( | N=775)     |      |       |        |

|                                   | Adjusted factors                          | P value |
|-----------------------------------|---|---------|
|                                   | being female aOR,<br>[95%CI] <sup>a</sup> |         |
| Demographic characteristics       |   |         |
| High school graduate and more     | 0.2 [0.1-0.4]                             | < 0.001 |
| Total income≥6.000.000            | 1.2 [0.7–1.9]                             | 0.529   |
| Unemployed                        | 1.9 [1.2–3.0]                             | 0.008   |
| Sex worker                        | 23.1 [9.2–57.8]                           | < 0.001 |
| Unstable housing last 6 months    | 2.6 [1.2-6.0]                             | 0.020   |
| Drug use behaviors                |   |         |
| Heroin injecting time < 5 years   | 1.6 [1.1–2.7]                             | 0.050   |
| Multi - drug use                  | 0.8 [0.4–1.4]                             | 0.449   |
| Methamphetamine positive in urine | 1.8 [1.1–3.1]                             | 0.021   |
| Psychosocial characteristics      |   |         |
| Thought of harming oneself        | 1.4 [0.7-3.0]                             | 0.334   |
| Risky practices                   |   |         |
| Unsafe sex activity               | 0.9 [0.5–1.7]                             | 0.715   |
| Partner ever injected drugs       | 34.1 [16.2–71.9]                          | < 0.001 |
| Methadone detected in urine       | 0.5 [0.3-0.8]                             | 0.008   |
| aM. E. 11. 2. Al. D2 0.215        |   |         |

<sup>a</sup> Mc Fadden's Adj  $R^2 = 0.315$ ;

for less than 5 years (38.1% vs. 26.1%, Chi-square = 8.67, p < 0.01). The number of heroin injections per day among FWID were significantly higher than MWID ( $2.5 \pm 1.0$  vs.  $2.2 \pm 0.9$ , t-test = -3.22, p < 0.001). FWID were more likely to have a positive urine test for methamphetamine compared to MWID (45.8% vs. 36.3%, Chi-square = 4.76, p < 0.05), while no difference in self-reported methamphetamine use data was found. There were no differences in needle/ syringes/water sharing between MWID and FWID, nor in the number of days injecting per month, in multi-drug use, in overdose and in non-injecting drug use.

FWID were more likely than MWID to report unsafe sex in the last six months (28.4% vs. 12.1%, Chi-square = 25.32, p < 0.001) and having a sex partner who ever injected drugs (38.1% vs. 2.3%, Chi-square = 186.33, p < 0.001).

### Comparison of Psychosocial Characteristics by Gender

With respect to depressive/anxiety symptoms in the last 2 weeks, FWID were more likely than MWID to have a thought of harming oneself (17.4% vs. 9.7%, Chi-square = 7.46, p < 0.05), while no differences were found for moderate/severe depressive/anxiety symptoms with the PHQ-4 (Table 1).

#### **Comparison of Access to care by Gender**

The proportion of FWID who had methadone detected in urine was significantly lower than MWID (36.8% vs. 51.3%, respectively, Chi-square = 10.46, p < 0.01) (Table 1). In terms of the HIV cascade of care, several differences should be pointed out. While all the 90-90-90 targets were achieved in MWID, there was still a small gap in the third '90 goal' for FWID; almost 30% who were HIV seropositive had an uncontrolled VL (threshold of 1000 copies/mL) while this proportion was of 17% for MWID (Fig. 2). Contact with peer-groups did not differ by gender (Table 1).

#### **Multivariable Associations with Gender**

In multivariable logistic regression (Table 2), being a FWID was independently associated with being unemployed (adjusted odds ratio (aOR)=1.9, 95% CI 1.2–3.0, p < 0.001), being sex worker (aOR=23.1, 95% CI 9.2–58.7, p < 0.001), having unstable housing (aOR=2.6, 95%CI 1.2-6.0, p < 0.05), reporting drug use for less than 5 years (aOR=1.6, 95%CI 1.1–2.7, p < 0.05), reporting higher rates of methamphetamine use (aOR=1.8, 95%CI 1.1–3.1, p < 0.05), and having a partner who ever injected drugs (aOR=34.1, 95%CI 16.2–71.9, p < 0.001). Negative associations were seen for those having a higher education level (aOR=0.2, 95%CI 0.1–0.4, p < 0.001) and less access to methadone treatment (aOR=0.5, 95%CI 0.3–0.8, p < 0.01). The Mc Fadden's Adj R<sup>2</sup> indicator for the final multivariable model was 0.315.

### Discussion

To our knowledge, this is the first study examining differences in gender among PWID in a high HIV and HCV burden setting in Asia. Hai Phong has experienced a high seroprevalence HIV epidemic among PWID that began in the 1990s with an estimated 4,000–6,000 PWID [25].

FWID in our study had clear differences compared to men, which could potentially increase risk for health damage and HIV/hepatitis C transmission [26–32]. FWID often

had lower levels of education, were more engaged in sex work, had greater difficulties finding work in the formal sector, and were more likely to have an unstable income and accommodations. Homelessness and unstable housing are strongly associated with an increased risk of HIV and HCV acquisition among PWID [33, 34]. Drug use and prostitution can become a vicious cycle in women's lives; while stimulants are often used to get more customers and to achieve higher incomes [35, 36], buying stimulants also requires having more clients. As a result, FWID who sell sex often face double stigma. The dangers to women may sometimes come from their own partners; in our study, more than one third of FWID had a primary sexual partner who used drugs, and women had a higher risk of depression/ anxiety and thoughts of harming oneself. FWID thus may have more difficulties normalizing their lives. These results are similar to studies of Manya Magnus et al. [26], Sabri et al. [27].

There was no difference in HIV and HCV infection prevalence among FWID and MWID. However, the lack of a difference in prevalence does not mean incidence is the same for each gender, as incidence might not be captured through the RDSS. Moreover, in this case-control comparison, the proportion of our study subjects reporting less than 5 years of injection drug use was higher among FWID compared to MWID, but the risk of HIV/HCV infection typically increases gradually over time for those reporting injection drug use, which has been shown in many previous studies [34, 37, 38]. In Hai Phong, HIV intervention programs implemented for the last 20 years have significantly controlled the spread of the disease, and the data from our cohort study clearly demonstrate that it is possible to achieve an end to an HIV epidemic among PWID in Hai Phong [39]. Nevertheless, there are differences on the third gap in the HIV cascade of care between FWID and MWID, which might be related to adherence, as access to ART is widely available and identification is typically not required. In contrast, HCV prevalence among PWID in Hai Phong remains extremely high and there is a lack of intervention strategies in the country as a whole [21]. In addition, the lower percentage of FWID with methadone positive urine compared to men points to inequalities in access to prevention services. With a sexist society like Vietnam, FWID, especially female sex workers, experience multiple forms of discrimination. They are often immigrants from other provinces, must stay in brothels, have no means of transportation and are controlled by their procurer. Meanwhile, the methadone treatment program, which is the only MOUD treatment available in Hai Phong, is quite strict in terms of administrative procedures, requiring support from relatives and daily medication [38]. Intersecting stigmas against PWID, especially FWID in the country, from all 3 sources of family, community,

and even health workers, might contribute to poor access to methadone treatment in FWID, which has been shown in several recent studies in Vietnam [40, 41]. Therefore, closer monitoring of ART, increased access to methadone treatment (take home methadone), implementing buprenorphine treatment and decreasing methamphetamine use should be considered in supporting this hard-to-reach population.

Our results echo those of other studies, with some differences: in a convenience sample of younger PWIDs, Doherty et al. found women at higher risk of HIV infection but women were not more likely to be injected by their sexual partner when initiating injection [28]. Evans et al. found no significant differences between MWID and FWID in terms of education level, race, and housing [42].

This study shows that FWID have different needs, risk factors, and behaviors compared to MWID. Future studies are needed to develop improved prevention strategies for this population. High rates of sex partners who have ever injected drugs, depressive/anxiety symptoms and methamphetamine use among FWID highlight the need for genderspecific prevention approaches to slow HIV transmission. As mentioned in several studies, FWID can be a bridge for HIV transmission to the general population via sex risk behaviors [43, 44]. By focusing on injecting and HIV-related sexual behavior, this study complements the gender disparities data by socio characterizing differences, psychological issues and access to treatment services. Future studies to evaluate PWID continue to be needed to extend our knowledge of this population more fully.

There were several limitations in this study. As with most studies on risk behaviors for drug use and sexual behaviors, much of the information is gathered through self-report and participants may have difficulty recalling information or there might be social desirability bias in reporting undesirable behaviors such as sex work or unsafe sex. Of note, the partner CBOs dedicated to support workers in DRIVE reported that sex work was underreported. As an interviewer-administered questionnaire, there may be differences with respect to the interviewer reading the questions or recording the responses, despite extensive training. Continuous quality control had been undertaken to avoid these errors. Finally, as this was a cross-sectional study, we cannot establish temporality with respect to the results reported.

# Conclusion

In the Vietnamese context, FWID have less access to MOUD including methadone, they experience limited effectiveness of ARV treatment, are at higher risk for methamphetamine use and sexual risk, and have more need for mental health care compared to MWID. Interventions targeting this vulnerable population are needed, possibly through community organizations and peer educators.

Acknowledgements This work was funded by NIDA (US) (grant number RO1 DA041978) and ANRS (French Agence Nationale de Recherches sur le Sida et les hépatites virales) (grant number ANRS 12353). The funding agencies had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

**Data Availability** The full data set contains highly sensitive information such as HIV serostatus and should not be made publicly available. The data can be made available through Data Use Agreements between a requester's institution and the Hai Phong University of Medicine and Pharmacy. Interested persons should contact the authors at Hai Phong University of Medicine and Pharmacy.

#### Declarations

**Conflict of interest** The authors declare that there are no conflicts of interest regarding the publication of this paper.

**Ethical Approval** The study was conducted in accordance with the NIDA procedures for protecting Human subjects and in respect with national legislations and regulations. The study protocol was approved by the Institutional Review Board of Haiphong University of Medicine and Pharmacy, and the Icahn School of Medicine.

**Informed Consent** Informed consent was obtained from all individual participants included in the study.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons. org/licenses/by/4.0/.

# References

- World Drug Report 2019: 35 Million People Worldwide Suffer from Drug Use Disorders While Only 1 in 7 People Receive Treatment Available online: https://www.unodc.org/lpo-brazil/ en/frontpage/2019/06/world-drug-report-2019\_-35-million-people-worldwide-suffer-from-drug-use-disorders-while-only-1-in-7-people-receive-treatment.html (accessed on 5 January 2022).
- Des Jarlais DC, Feelemyer JP, Modi SN, Arasteh K, Hagan H. Are females who inject drugs at higher risk for HIV infection than males who inject drugs: an international systematic review of high seroprevalence areas. Drug Alcohol Depend. 2012;124:95– 107. doi:https://doi.org/10.1016/j.drugalcdep.2011.12.020.
- UNODC. Women Who Inject Drugs and HIV: Addressing Specific Needs 2014.
- Iversen J, Page K, Madden A, Maher LHIV. HCV and Health-Related Harms among Women who inject drugs:

implications for Prevention and Treatment. J Acquir Immune Defic Syndr. 2015;69:176–81. doi:https://doi.org/10.1097/ QAI.000000000000659.

- Larney S, Mathers BM, Poteat T, Kamarulzaman A, Degenhardt L. Global epidemiology of HIV among Women and Girls who use or inject drugs: current knowledge and Limitations of existing data. J Acquir Immune Defic Syndr. 2015;69:100–9. doi:https:// doi.org/10.1097/QAI.00000000000623.
- El-Bassel N, Shaw SA, Dasgupta A, Strathdee SA. Drug Use as a driver of HIV Risks: re-emerging and emerging issues. Curr Opin HIV AIDS. 2014;9:150–5. doi:https://doi.org/10.1097/ COH.000000000000035.
- Shannon K, Csete J, Violence. Condom negotiation, and HIV/STI risk among sex workers. JAMA. 2010;304:573–4. doi:https://doi. org/10.1001/jama.2010.1090.
- El-Bassel N, Gilbert L, Wu E, Go H, Hill JHIV. and Intimate Partner Violence among Methadone-Maintained Women in New York City. Soc Sci Med. 2005;61:171–83. doi:https://doi.org/10.1016/j. socscimed.2004.11.035.
- Global HIV. & AIDS Statistics Fact Sheet Available online: https://www.unaids.org/en/resources/fact-sheet (accessed on 20 October 2021).
- Kamel-Khodabandeh A, Mirzaee M, Jahani Y, Sharifi H. Sex under influence of drugs: a Nationwide Survey among iranian female sex workers. Addict Health. 2018;10:205–15. doi:https:// doi.org/10.22122/ahj.v10i4.566.
- UNAIDS. HIV and AIDS Estimates in Viet Nam. 2020. Available online: https://www.unaids.org/en/regionscountries/countries/ vietnam (accessed on 5 January 2022).
- UNAIDS & VAAC. A review of HIV Prevention in Vietnam 2019. Available Online Https://Unaids.Org.vn/ Wp-Content/Uploads/2020/03/Prevention-Review-Report\_ ENG Final-14102019.Pdf.
- Vinh VH, Vallo R, Giang HT, Huong DT, Oanh KTH, Khue PM, Thanh NTT, Quillet C, Rapoud D, Michel L, et al. A Cohort Study revealed high mortality among people who inject drugs in Hai Phong, Vietnam. J Clin Epidemiol. 2021;139:38–48. doi:https:// doi.org/10.1016/j.jclinepi.2021.07.007.
- Rudolph AE, Davis WW, Quan VM, Ha TV, Minh NL, Gregowski A, Salter M, Celentano DD, Go V. Perceptions of Community and Family Level IDU and HIV Related Stigma, Disclosure decisions and experiences with layered stigma among HIV positive injection drug users in Vietnam. AIDS Care. 2012;24:239–44. doi:https://doi.org/10.1080/09540121.2011.596517.
- Pham Minh K, Vallo R, Duong Thi H, Khuat Thi Hai O, Jarlais DCD, Peries M, Le SM, Rapoud D, Quillet C, Nham Thi TT, et al. Psychiatric Comorbidities among People Who Inject Drugs in Hai Phong, Vietnam: The Need for Screening and Innovative Interventions. *Biomed Res Int* 2018, 2018, 8346195, doi:https:// doi.org/10.1155/2018/8346195.
- Quan VM, Chung A, Abdul-Quader AS. The feasibility of a syringe-needle-exchange program in Vietnam. Subst Use Misuse. 1998;33:1055–67. doi:https://doi. org/10.3109/10826089809062206.
- Nguyen TTM, Nguyen LT, Pham MD, Vu HH, Mulvey KP Methadone Maintenance Therapy in Vietnam: An Overview and Scaling-Up Plan. *Adv Prev Med* 2012, *2012*, 732484, doi:https:// doi.org/10.1155/2012/732484.
- World Health Organization. Good practice in Asia: targeted HIV Prevention for IDU and Sex Workers. Vietnam: Vietnam's First Large-Scale National Harm Reduction Initiative WHO/WPRO and Partners. Hanoi; 2010.
- 19. Hoang TV, Ha TTT, Hoang TM, Nhu NT, Quoc NC, Tam N thi Mills M, S. Impact of a Methadone Maintenance Therapy Pilot

in Vietnam and Its Role in a Scaled-up Response. *Harm Reduct J* 2015, *12*, 39, doi:https://doi.org/10.1186/s12954-015-0075-9.

- Kato M, Long NH, Duong BD, Nhan DT, Nguyen TTV, Hai NH, Giang LM, Hoa DM, Van NT, Suthar AB, et al. Enhancing the benefits of antiretroviral therapy in Vietnam: towards ending AIDS. Curr HIV/AIDS Rep. 2014;11:487–95. doi:https://doi. org/10.1007/s11904-014-0235-7.
- Molès J-P, Vallo R, Khue PM, Huong DT, Oanh KTH, Thoa NT, Giang HT, Thanh NTT, Vinh VH, Bui Thi TA, et al. HIV Control Programs reduce HIV incidence but not HCV incidence among people who inject drugs in HaiPhong, Vietnam. Sci Rep. 2020;10:6999. doi:https://doi.org/10.1038/s41598-020-63990-w.
- Kroenke K, Spitzer RL, Williams JBW, Löwe B. An Ultra-Brief Screening Scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009;50:613–21. doi:https://doi.org/10.1176/appi. psy.50.6.613.
- Vietnamese Ministry of Health. Vietnamese National Guidelines for HIV Testing (Quyét Định 2674/QĐ-BYT 2018 Ban Hành Hướng Dẫn Quốc Gia Xét Nghiệm HIV) Available online: https://thukyluat.vn/vb/quyet-dinh-2674-qd-byt-2018-ban-hanhhuong-dan-quoc-gia-xet-nghiem-hiv-5d143.html (accessed on 4 November 2021).
- Hu B, Shao J, Palta M. PSEUDO-R 2 in logistic regression model. Statistica Sinica. 2006;16:847–60.
- 25. Des Jarlais D, Khue PM, Feelemyer J, Arasteh K, Thi Huong D, Thi Hai Oanh K, Thi Giang H, Thi Tuyet Thanh N, Vinh VH, Heckathorn DD, et al. Using Dual Capture/Recapture studies to Estimate the Population size of persons who inject drugs (PWID) in the City of Hai Phong, Vietnam. Drug Alcohol Depend. 2018;185:106–11. doi:https://doi.org/10.1016/j. drugalcdep.2017.11.033.
- Magnus M, Kuo I, Phillips G, Rawls A, Peterson J, Montanez L, West-Ojo T, Jia Y, Opoku J, Kamanu-Elias N, et al. Differing HIV Risks and Prevention needs among men and women injection drug users (IDU) in the District of Columbia. J Urban Health. 2013;90:157–66. doi:https://doi.org/10.1007/s11524-012-9687-5.
- Sabri B, McFall AM, Solomon SS, Srikrishnan AK, Vasudevan CK, Anand S, Celentano DD, Mehta SH, Kumar S, Lucas GM. Gender differences in factors related to HIV Risk Behaviors among people who inject drugs in North-East India. PLoS ONE. 2017;12:e0169482. doi:https://doi.org/10.1371/journal. pone.0169482.
- Doherty MC, Garfein RS, Monterroso E, Latkin C, Vlahov D. Gender differences in the initiation of Injection Drug Use among Young adults. J Urban Health. 2000;77:396–414. doi:https://doi. org/10.1007/BF02386749.
- 29. Women and Gender Issues Related to Drugs | Www.Emcdda. Europa.Eu Available online: https://www.emcdda.europa.eu/topics/women\_en (accessed on 6 May 2021).
- Valencia J, Alvaro-Meca A, Troya J, Gutiérrez J, Ramón C, Rodríguez A, Vázquez-Morón S, Resino S, Moreno S, Ryan P. Gender-based vulnerability in women who inject drugs in a harm reduction setting. PLoS ONE. 2020;15:e0230886. doi:https://doi. org/10.1371/journal.pone.0230886.
- Loeliger KB, Marcus R, Wickersham JA, Pillai V, Kamarulzaman A, Altice FL. The Syndemic of HIV, HIV-Related risk and multiple co-morbidities among women who use drugs in Malaysia: important targets for intervention. Addict Behav. 2016;53:31–9. doi:https://doi.org/10.1016/j.addbeh.2015.09.013.
- Higgins JA, Hoffman S, Dworkin SL, Rethinking, Gender. Heterosexual men, and women's vulnerability to HIV/AIDS. Am J Public Health. 2010;100:435–45. doi:https://doi.org/10.2105/ AJPH.2009.159723.
- Arum C, Fraser H, Artenie AA, Bivegete S, Trickey A, Alary M, Astemborski J, Iversen J, Lim AG, MacGregor L, et al.

Homelessness, unstable housing, and risk of HIV and Hepatitis C Virus Acquisition among people who inject drugs: a systematic review and Meta-analysis. Lancet Public Health. 2021;6:e309–23. doi:https://doi.org/10.1016/S2468-2667(21)00013-X.

- 34. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham EB, Trickey A, Dumchev K, et al. Global prevalence of Injecting Drug Use and Sociodemographic characteristics and prevalence of HIV, HBV, and HCV in People who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5:e1192–207. doi:https://doi.org/10.1016/ S2214-109X(17)30375-3.
- 35. Shannon K, Strathdee S, Shoveller J, Zhang R, Montaner J, Tyndall, M CRYSTAL METHAMPHETAMINE USE AMONG FEMALE STREET-BASED SEX WORKERS. MOVING BEYOND INDIVIDUAL-FOCUSED INTERVENTIONS. Drug Alcohol Depend 2011, 113, 76–81, doi:https://doi.org/10.1016/j. drugalcdep.2010.07.011.
- Couture M-C, Evans JL, Sothy NS, Stein ES, Sichan K, Maher L, Page K. Correlates of amphetamine-type Stimulants Use and Associations with HIV-Related risks among Young Women Engaged in Sex Work in Phnom Penh, Cambodia. Drug Alcohol Depend. 2012;120:119–26. doi:https://doi.org/10.1016/j. drugalcdep.2011.07.005.
- 37. Semá Baltazar C, Boothe M, Kellogg T, Ricardo P, Sathane I, Fazito E, Raymond HF, Temmerman M, Luchters S. Prevalence and risk factors Associated with HIV/Hepatitis B and HIV/ Hepatitis C Co-Infections among people who inject drugs in Mozambique. BMC Public Health. 2020;20:851. doi:https://doi. org/10.1186/s12889-020-09012-w.
- Giang LM, Ngoc LB, Hoang VH, Mulvey K, Rawson RA. Substance Use Disorders and HIV in Vietnam since Doi Moi (renovation): an overview. J Food Drug Anal. 2013;21:42–5. doi:https:// doi.org/10.1016/j.jfda.2013.09.032.
- 39. Des Jarlais DC, Huong DT, Oanh KTH, Feelemyer JP, Arasteh K, Khue PM, Giang HT, Thanh NTT, Vinh VH, Le SM, et al. Ending an HIV epidemic among persons who inject drugs in a Middle-Income Country: extremely low HIV incidence among persons who inject drugs in Hai Phong, Viet Nam. AIDS. 2020;34:2305– 11. doi:https://doi.org/10.1097/QAD.00000000002712.
- 40. Do M, Ho HT, Dinh HT, Le HH, Truong TQ, Dang TV, Nguyen DD, Andrinopoulos K. Intersecting stigmas among HIV-Positive people who inject drugs in Vietnam. Health Serv Insights. 2021;14:11786329211013552. doi:https://doi. org/10.1177/11786329211013552.
- 41. Le LT, Grau LE, Nguyen HH, Khuat OHT, Heimer R. Coalition Building by Drug user and sex Worker Community-Based Organizations in Vietnam Can lead to Improved interactions with Government Agencies: a qualitative study. Harm Reduct J 2015, 12, doi:https://doi.org/10.1186/s12954-015-0070-1.
- 42. Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, Moss AR. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health. 2003;80:137–46. doi:https://doi.org/10.1093/jurban/jtg137.
- Nguyen NT, Nguyen HT, Trinh HQ, Mills SJ, Detels R. Clients of female sex workers as a Bridging Population in Vietnam. AIDS Behav. 2009;13:881–91. doi:https://doi.org/10.1007/ s10461-008-9463-4.
- 44. Shah NS, Shiraishi RW, Subhachaturas W, Anand A, Whitehead SJ, Tanpradech S, Manopaiboon C, Sabin KM, Fox KK, Kim AY. Bridging populations-sexual risk behaviors and HIV Prevalence in clients and partners of female sex workers, Bangkok, Thailand 2007. J Urban Health. 2011;88:533–44. doi:https://doi.org/10.1007/s11524-010-9542-5.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

# **Authors and Affiliations**

Hoang Thi Giang<sup>1</sup> · Nguyen Quang Duc<sup>1</sup> · Pham Minh Khue<sup>1</sup> · Catherine Quillet<sup>2</sup> · Khuat Thi Hai Oanh<sup>3</sup> · Nham Thi Tuyet Thanh<sup>3</sup> · Roselyne Vallo<sup>2</sup> · Jonathan Feelemyer<sup>4</sup> · Vu Hai Vinh<sup>5</sup> · Delphine Rapoud<sup>2</sup> · Laurent Michel<sup>6</sup> · Didier Laureillard<sup>2,7</sup> · Jean Pierre Moles<sup>2</sup> · Don Des Jarlais<sup>4</sup> · Nicolas Nagot<sup>2</sup> · Duong Thi Huong<sup>1</sup>

⊠ Hoang Thi Giang hoanggiang0708@gmail.com

> Nguyen Quang Duc quangduc589@gmail.com

Pham Minh Khue pmkhue@hpmu.edu.vn

Catherine Quillet catherine\_quillet@yahoo.fr

Khuat Thi Hai Oanh oanhkhuat@scdi.org.vn

Nham Thi Tuyet Thanh thanhnham@scdi.org.vn

Roselyne Vallo roselyne.vallo@umontpellier.fr

Jonathan Feelemyer jf3880@nyu.edu

Vu Hai Vinh

vinhvuhai@gmail.com

Delphine Rapoud delphine.rapoud@yahoo.fr

Laurent Michel laurent.michel@croix-rouge.fr

Didier Laureillard didier.laureillard@yahoo.fr

Jean Pierre Moles JEAN-PIERRE.MOLES@inserm.fr

Don Des Jarlais don.desjarlais@nyu.edu

Nicolas Nagot n-nagot@chu-montpellier.fr

Duong Thi Huong dthuong@hpmu.edu.vn

- <sup>1</sup> Faculty of Public Health, Haiphong University of Medicine and Pharmacy, 72A, Nguyen Binh Khiem, Ngo Quyen district, Haiphong city, Vietnam
- <sup>2</sup> Pathogenesis and control of chronic & emerging infections, Etablissement Français du Sang, University of Montpellier, INSERM, University of Antilles, Montpellier, France
- <sup>3</sup> Supporting Community Development Initiatives, Hanoi, Vietnam
- <sup>4</sup> New-York University, NewYork, NY, USA
- <sup>5</sup> Dept of Infectious and Tropical Diseases, Viet Tiep Hospital, Hai Phong, Vietnam
- <sup>6</sup> Pierre Nicole Center, CESP/Inserm 1018, French Red Cross, Paris, France
- <sup>7</sup> Infectious Diseases Department, Caremeau University Hospital, Nîmes, France